Back

Phase 2 study of A797, an oral, selective p38 mitogen-activated protein kinase inhibitor, in patients with lamin A/C-related dilated cardiomyopathy

30 August 2016 (10:19 - 10:26)
Organised by:
Congress Presentation Part of: Cardiomyopathies Pharmacologic therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Calum MacRae

Harvard Medical School, Boston (United States of America)

6 More presentations in this session

Presentation thumbnail
Gender differences in the development of CMR abnormalities and cardiac complications: a multicentric prospective study in a large cohort of thalassemia major patients
Doctor A. Pepe (Pisa, IT)
Abstract Slides
Presentation thumbnail
Long time clinical course of cardiac sarcoidosis: retrospective cohort analysis in Japan
Doctor T. Nagayama (Osaka, JP)
Abstract Slides
Presentation thumbnail
Incident heart failure in patients with rheumatoid arthritis: a nationwide cohort study
Doctor U. Khalid (Hellerup, DK)
Abstract Slides
Presentation thumbnail
Cardiomyocyte bulking is a novel predictor of left ventricular reverse remodeling in patients with dilated cardiomyopathy
Mr K. Fukaya (Nagoya, JP)
Abstract
Presentation thumbnail
Eosinophilic myocarditis in patients on dobutamine therapy: an underappreciated but not uncommon phenomenon
Doctor M. Barrett (Dublin, IE)
Abstract Slides

Access the full session

Session thumbnail
Cardiomyopathies

The Event

Event poster

ESC Congress 2016

30 August 2016 10:19 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources